STATE-OF-THE-ART PAPER
Inflammation and Atherothrombosis
From Population Biology and Bench Research to Clinical Practice
Peter Libby, MD*, ,* and
Paul M. Ridker, MD, MPH*, ,
* Division of Cardiovascular Medicine, Center for Cardiovascular Disease Prevention
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital
Harvard Medical School, Boston, Massachusetts
Manuscript received November 29, 2005;
revised manuscript received June 6, 2006,
accepted June 13, 2006.
* Reprint requests and correspondence: Dr. Peter Libby, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB 741, Boston, Massachusetts 02115. (Email: plibby{at}rics.bwh.harvard.edu).
The concept that inflammation governs atherosclerosis and its complications has provided a new unifying hypothesis of the links between risk factors and the cellular and molecular alterations that underlie this disease. This new mechanistic insight has already begun to translate into changes in clinical practice. The preponderance of available data supports the predictive power of biomarkers of inflammation such as high-sensitivity C-reactive protein (hsCRP) in broad categories of individuals, both those who are apparently well and those with already-manifest atherosclerotic cardiovascular disease. The demonstrated clinical utility of hsCRP and potentially of other inflammatory biomarkers has engendered intense interest in evaluating their cost-effectiveness as predictive tools beyond conventional risk markers and as goals for therapy. The rapid translation of inflammation biology in cardiovascular disease from the laboratory to the clinic serves as a gratifying example of bench-to-bedside research. Ultimately, the insight that inflammation plays a fundamental role in atherosclerosis may lead to novel therapies that target aspects of the inflammatory process smoldering within the atheroma.
|
Abbreviations and Acronyms
| | EC = endothelial cell | | ECM = extracellular matrix | | HDL = high-density lipoprotein | | hsCRP = high-sensitivity C-reactive protein | | IL = interleukin | | LDL-C = low-density lipoprotein cholesterol | | ·NO = nitric oxide | | SMC = smooth muscle cell |
|
This article has been cited by other articles:
|
|
|
|
 
M. M. McDermott and D. M. Lloyd-Jones
The role of biomarkers and genetics in peripheral arterial disease.
J. Am. Coll. Cardiol.,
September 29, 2009;
54(14):
1228 - 1237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Leon and U. G. Bronas
Pathophysiology of Coronary Heart Disease and Biological Mechanisms for the Cardioprotective Effects of Regular Aerobic Exercise
American Journal of Lifestyle Medicine,
September 1, 2009;
3(5):
379 - 385.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Mora, K. Musunuru, and R. S. Blumenthal
The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines
Clin. Chem.,
February 1, 2009;
55(2):
219 - 228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Ridker
C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease
Clin. Chem.,
February 1, 2009;
55(2):
209 - 215.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Osto, C. M. Matter, A. Kouroedov, T. Malinski, M. Bachschmid, G. G. Camici, U. Kilic, T. Stallmach, J. Boren, S. Iliceto, et al.
c-Jun N-Terminal Kinase 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress
Circulation,
November 11, 2008;
118(20):
2073 - 2080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Waldeck, F. Hager, C. Holtke, C. Lanckohr, A. von Wallbrunn, G. Torsello, W. Heindel, G. Theilmeier, M. Schafers, and C. Bremer
Fluorescence Reflectance Imaging of Macrophage-Rich Atherosclerotic Plaques Using an {alpha}v{beta}3 Integrin-Targeted Fluorochrome
J. Nucl. Med.,
November 1, 2008;
49(11):
1845 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Apovian, S. Bigornia, M. Mott, M. R. Meyers, J. Ulloor, M. Gagua, M. McDonnell, D. Hess, L. Joseph, and N. Gokce
Adipose Macrophage Infiltration Is Associated With Insulin Resistance and Vascular Endothelial Dysfunction in Obese Subjects
Arterioscler Thromb Vasc Biol,
September 1, 2008;
28(9):
1654 - 1659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bobik
Apolipoprotein CIII and Atherosclerosis: Beyond Effects on Lipid Metabolism
Circulation,
August 12, 2008;
118(7):
702 - 704.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B Panagiotakos, C. Pitsavos, C. Chrysohoou, I. Skoumas, and C. Stefanadis
Five-year incidence of cardiovascular disease and its predictors in Greece: the ATTICA study
Vascular Medicine,
May 1, 2008;
13(2):
113 - 121.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Clarke, J. R. Emberson, E. Breeze, J. P. Casas, S. Parish, A. D. Hingorani, A. Fletcher, R. Collins, and L. Smeeth
Biomarkers of inflammation predict both vascular and non-vascular mortality in older men
Eur. Heart J.,
March 2, 2008;
29(6):
800 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Conen, B M Everett, R J Glynn, and P M Ridker
Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial
Heart,
March 1, 2008;
94(3):
e13 - e13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. S. Packard and P. Libby
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Clin. Chem.,
January 1, 2008;
54(1):
24 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Punjabi, B. A. Beamer, A. Jain, M. E. Spencer, and N. Fedarko
Elevated Levels of Neopterin in Sleep-Disordered Breathing
Chest,
October 1, 2007;
132(4):
1124 - 1130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Ridker
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus
J. Am. Coll. Cardiol.,
May 29, 2007;
49(21):
2129 - 2138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. Jaffer, D.-E. Kim, L. Quinti, C.-H. Tung, E. Aikawa, A. N. Pande, R. H. Kohler, G.-P. Shi, P. Libby, and R. Weissleder
Optical Visualization of Cathepsin K Activity in Atherosclerosis With a Novel, Protease-Activatable Fluorescence Sensor
Circulation,
May 1, 2007;
115(17):
2292 - 2298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Libby
Fat Fuels the Flame: Triglyceride-Rich Lipoproteins and Arterial Inflammation
Circ. Res.,
February 16, 2007;
100(3):
299 - 301.
[Full Text]
[PDF]
|
|
|
|
